Annual Cancer Treatment Costs Exceeded 156 Billion Dollars in the USA Alone

According to new findings, treatment for patients with the 15 most common cancers in the USA cost more than 156 billion dollars in 2018.
Healthcare costs generally continue to rise over the years, and the trend is particularly clear in cancer care. Oncology drug prices are increasing, with some costing more than 1 million dollars per patient annually. Despite this rise, estimates of the resources and spending devoted to cancer treatment for privately insured patients remain limited in the USA and many other countries.
To better understand the most common and costly services, Associate Professor Dr. Nicholas Zaorsky from the Department of Radiation Oncology and Public Health at Penn State College of Medicine and researchers from Penn State Cancer Institute analyzed data from MarketScan, a large private insurance database. On October 6, 2021, in their results published online in JAMA, they noted that, with Medicaid (the American program providing health coverage to low-income adults, children, pregnant women, older people or people with disabilities) and private insurance accounting for an increasing share of cancer costs, "our study helps highlight the areas most likely to be associated with this increase in spending".
Treatment and Care Costs by Cancer Type
The analysis, including data from 402,115 privately insured patients under age 65 with the 15 most common cancers, found that the estimated total cost of cancer treatment reached 156.2 billion dollars in 2018. When Zaorsky and his team analyzed costs by cancer type and service, they found 38.4 million documented procedure codes totaling 10.8 billion dollars for 15 cancers. Breast, colorectal and prostate cancer had the largest numbers of services, at 10.9 million, 3.9 million and 3.6 million, respectively.
- Breast cancer was also the most common (124,543) and most expensive cancer to care for, with a reported total cost of 3.4 billion dollars (31.5%).
- Lung and colorectal cancer were the second most expensive, with treatment costing 1.1 billion dollars for each.
- They were followed by lymphoma at 1.02 billion dollars and prostate cancer at 832 million dollars.
- Of the seven service categories examined, pathology and laboratory testing were the most common, representing more than 30% (11.7 million) of the 38.4 million dollars in services.
- These were followed by medical services at 16.4% (6.3 million), and medical supplies and other services at just under 16% (6.1 million).
The largest expenditure was 4 billion dollars on medical supplies, including anticancer drugs and other services (37% of 10.8 billion dollars), followed by radiology at 2.1 billion dollars (19.4%) and surgery at 1.8 billion dollars (16.7%).
Do Higher Costs Improve Care Quality?
Studies have shown that these high costs are generally not defensible in terms of clinical benefit, emphasizing that "more research is needed to determine how much of these costs are unnecessary or how far they improve the quality of care."
Arjun Gupta, who was not involved in the research, noted that two of the 10 most expensive medicines —pegfilgrastim and denosumab—were for supportive care, and that eight of the 10 most frequently used medicines —including antiemetics such as dexamethasone, ondansetron and palonosetron, and pain/sedation medicines such as fentanyl— were for supportive care. Associate Professor Dr. Gupta, from the Division of Hematology, Oncology and Transplantation at the University of Minnesota Medical School, said, "Spending on supportive care services can contribute substantially to total spending and patients' out-of-pocket spending. Although we cannot assess appropriateness here, other studies tell us that some of this use is unnecessary."
According to Zaorsky and his team, the evolving insurance landscape may explain the increasing share of cancer costs paid by private insurance and Medicaid. "One reason is that the Patient Protection and Affordable Care Act substantially expanded Medicaid coverage and removed some barriers to private coverage, such as preexisting-condition exclusions.
Second, private (self-funded) payers tend to pay substantially higher rates for care. As new, high-cost cancer treatments enter the market, private payers inevitably pay much more both overall and relative to other payers. Third, colorectal and human papillomavirus-related cancer rates are rising in some patient groups under age 65, so private payers and Medicaid face relatively higher cancer treatment costs."
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.